Integrated analysis reveals SMARCD1 is a potential biomarker and therapeutic target in skin cutaneous melanoma.
Bioinformatics analysis
Biomarker
SMARCD1
Skin cutaneous melanoma
Therapeutic
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
07
06
2023
accepted:
29
06
2023
medline:
31
8
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
SMARCD1 is a part of the SWI/SNF chromatin remodeling complex family, which consists of transcription factors that are implicated in various types of cancer. Examining SMARCD1 expression in human cancers can provide valuable insights into the development and progression of skin cutaneous melanoma (SKCM). Our study comprehensively examined the association between SMARCD1 expression and numerous factors, including prognosis, tumor microenvironment (TME), immune infiltration, tumor mutational burden (TMB), and microsatellite instability (MSI) in SKCM. Then we utilized immunohistochemical staining to measure the SMARCD1 expression in both SKCM tissues and normal skin tissues. Furthermore, we conducted in vitro experimentation to evaluate the effects of SMARCD1 knockdown on SKCM cells. We found that aberrant expression of SMARCD1 across 16 cancers was strongly correlated with overall survival (OS) and progression-free survival (PFS). In addition, our research revealed that SMARCD1 expression is associated with multiple factors in different types of cancer, including immune infiltration, TME, immune-related genes, MSI, TMB, and sensitivity to anti-cancer drugs. SMARCD1 is likely involved in various SKCM signaling pathways and biological processes. Additionally, our research revealed that an SMARCD1-based risk factor model accurately predicted OS in SKCM patients. Furthermore, the downregulation of SMARCD1 expression demonstrated a significant inhibition of SKCM cell proliferation and migration, as well as an increase in apoptosis and cell cycle arrest. We conclude that SMARCD1 is a promising diagnostic, prognostic, and therapeutic biomarker for SKCM, and its expression has significant clinical implications for the development of novel treatment strategies.
Identifiants
pubmed: 37401939
doi: 10.1007/s00432-023-05064-8
pii: 10.1007/s00432-023-05064-8
doi:
Substances chimiques
Biomarkers
0
SMARCD1 protein, human
0
Chromosomal Proteins, Non-Histone
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
11619-11634Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Adduri R, George SA, Kavadipula P, Bashyam MD (2020) SMARCD1 is a transcriptional target of specific non-hotspot mutant p53 forms. J Cell Physiol 235(5):4559–4570
doi: 10.1002/jcp.29332
pubmed: 31637714
Akrami H, Moradi B, Borzabadi FD, Mehdizadeh K (2018) Ibuprofen reduces cell proliferation through inhibiting Wnt/beta catenin signaling pathway in gastric cancer stem cells. Cell Biol Int 42(8):949–958
doi: 10.1002/cbin.10959
pubmed: 29512256
Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI (2022) Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther 24:0108301
doi: 10.1016/j.pharmthera.2022.108301
Bhave P, Wong J, McInerney-Leo A, Cust AE, Lawn C, Janda M, Mar VJ (2023) Management of cutaneous melanoma in Australia: a narrative review. Med J Aust 218:426
doi: 10.5694/mja2.51910
pubmed: 37120760
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
doi: 10.3322/caac.21492
pubmed: 30207593
Campbell EH, Reinhart JP, Crum OM, Proffer SL, Weaver A, Gibson LE, Brewer JD, Demer AM (2023) Increasing incidence and decreasing mortality of cutaneous melanoma in middle-aged adults: an epidemiologic study in Olmsted county, Minnesota. Mayo Clin Proc 98(5):713–722
doi: 10.1016/j.mayocp.2022.10.029
pubmed: 37137643
Chen L, Fulcoli FG, Ferrentino R, Martucciello S, Illingworth EA, Baldini A (2012) Transcriptional control in cardiac progenitors: Tbx1 interacts with the BAF chromatin remodeling complex and regulates Wnt5a. PLoS Genet 8(3):e1002571
doi: 10.1371/journal.pgen.1002571
pubmed: 22438823
pmcid: 3305383
Donizy P, Krzyzinski M, Markiewicz A, Karpinski P, Kotowski K, Kowalik A, Orlowska-Heitzman J, Romanowska-Dixon B, Biecek P, Hoang MP (2022) Machine learning models demonstrate that clinicopathologic variables are comparable to gene expression prognostic signature in predicting survival in uveal melanoma. Eur J Cancer 17:4251–4260
Forschner A, Battke F, Hadaschik D, Schulze M, Weissgraeber S, Han CT, Kopp M, Frick M, Klumpp B, Tietze N, Amaral T, Martus P, Sinnberg T, Eigentler T, Keim U, Garbe C, Docker D, Biskup S (2019) Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study. J Immunother Cancer 7(1):180
doi: 10.1186/s40425-019-0659-0
pubmed: 31300034
pmcid: 6625062
Garbe C, Amaral T, Peris K, Hauschild A, Arenberger P, Basset-Seguin N, Bastholt L, Bataille V, Del MV, Dreno B, Fargnoli MC, Forsea AM, Grob JJ, Hoeller C, Kaufmann R, Kelleners-Smeets N, Lallas A, Lebbe C, Lytvynenko B, Malvehy J, Moreno-Ramirez D, Nathan P, Pellacani G, Saiag P, Stratigos AJ, van Akkooi A, Vieira R, Zalaudek I, Lorigan P (2022) European consensus-based interdisciplinary guideline for melanoma. Part 2: treatment-update 2022. Eur J Cancer 17:0256–0284
doi: 10.1016/j.ejca.2022.04.018
Georgescu SR, Tampa M, Mitran CI, Mitran MI, Caruntu C, Caruntu A, Lupu M, Matei C, Constantin C, Neagu M (2020) Tumour microenvironment in skin carcinogenesis. Adv Exp Med Biol 12:26123–26142
Guo S, Chen J, Yi X, Lu Z, Guo W (2022) Identification and validation of ferroptosis-related lncRNA signature as a prognostic model for skin cutaneous melanoma. Front Immunol 13:985051
doi: 10.3389/fimmu.2022.985051
pubmed: 36248853
pmcid: 9556814
Han B, Yang M, Liu Q, Wang G, Hou J (2022) Long noncoding RNA SBF2-AS1 promotes abdominal aortic aneurysm formation through the miRNA-520f-3p/SMARCD1 axis. Dis Markers 20:224782361
Hsiao PW, Fryer CJ, Trotter KW, Wang W, Archer TK (2003) BAF60a mediates critical interactions between nuclear receptors and the BRG1 chromatin-remodeling complex for transactivation. Mol Cell Biol 23(17):6210–6220
doi: 10.1128/MCB.23.17.6210-6220.2003
pubmed: 12917342
pmcid: 180928
Inoue C, Zhao C, Tsuduki Y, Udono M, Wang L, Nomura M, Katakura Y (2017) SMARCD1 regulates senescence-associated lipid accumulation in hepatocytes. NPJ Aging Mech Dis 3:11
doi: 10.1038/s41514-017-0011-1
pmcid: 5577293
Kadoch C, Hargreaves DC, Hodges C, Elias L, Ho L, Ranish J, Crabtree GR (2013) Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet 45(6):592–601
doi: 10.1038/ng.2628
pubmed: 23644491
pmcid: 3667980
Kang K, Xie F, Mao J, Bai Y, Wang X (2020) Significance of tumor mutation burden in immune infiltration and prognosis in cutaneous melanoma. Front Oncol 10:573141
doi: 10.3389/fonc.2020.573141
pubmed: 33072607
pmcid: 7531222
Karami FM, Azargoonjahromi A, Soofi A, Almasi F, Hosseinzadeh S, Khalili S, Sheikhi K, Ferdousmakan S, Owrangi S, Fahimi M, Zalpoor H, Nabi AM, Payandeh Z, Pourzardosht N (2022) Current understanding of epigenetics role in melanoma treatment and resistance. Cancer Cell Int 22(1):313
doi: 10.1186/s12935-022-02738-0
Kwon M, Hong JY, Kim ST, Kim KM, Lee J (2020) Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. Pathol Res Pract 216(6):152947
doi: 10.1016/j.prp.2020.152947
pubmed: 32284250
Lopes J, Rodrigues C, Gaspar MM, Reis CP (2022) How to treat melanoma? The current status of innovative nanotechnological strategies and the role of minimally invasive approaches like PTT and PDT. Pharmaceutics 14(9):1817
doi: 10.3390/pharmaceutics14091817
pubmed: 36145569
pmcid: 9504126
Oh J, Sohn DH, Ko M, Chung H, Jeon SH, Seong RH (2008) BAF60a interacts with p53 to recruit the SWI/SNF complex. J Biol Chem 283(18):11924–11934
doi: 10.1074/jbc.M705401200
pubmed: 18303029
Rebecca VW, Somasundaram R, Herlyn M (2020) Pre-clinical modeling of cutaneous melanoma. Nat Commun 11(1):2858
doi: 10.1038/s41467-020-15546-9
pubmed: 32504051
pmcid: 7275051
Ring HZ, Vameghi-Meyers V, Wang W, Crabtree GR, Francke U (1998) Five SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are dispersed in the human genome. Genomics 51(1):140–143
doi: 10.1006/geno.1998.5343
pubmed: 9693044
Rozanc J, Sakellaropoulos T, Antoranz A, Gutta C, Podder B, Vetma V, Rufo N, Agostinis P, Pliaka V, Sauter T, Kulms D, Rehm M, Alexopoulos LG (2019) Phosphoprotein patterns predict trametinib responsiveness and optimal trametinib sensitisation strategies in melanoma. Cell Death Differ 26(8):1365–1378
doi: 10.1038/s41418-018-0210-8
pubmed: 30323272
Shen J, Xiao Z, Wu WK, Wang MH, To KF, Chen Y, Yang W, Li MS, Shin VY, Tong JH, Kang W, Zhang L, Li M, Wang L, Lu L, Chan RL, Wong SH, Yu J, Chan MT, Chan FK, Sung JJ, Cheng AS, Cho CH (2015) Epigenetic silencing of miR-490-3p reactivates the chromatin remodeler SMARCD1 to promote Helicobacter pylori-induced gastric carcinogenesis. Cancer Res 75(4):754–765
doi: 10.1158/0008-5472.CAN-14-1301
pubmed: 25503559
Shenenberger DW (2012) Cutaneous malignant melanoma: a primary care perspective. Am Fam Physician 85(2):161–168
pubmed: 22335216
Strashilov S, Yordanov A (2021) Aetiology and pathogenesis of cutaneous melanoma: current concepts and advances. Int J Mol Sci 22(12):6395
doi: 10.3390/ijms22126395
pubmed: 34203771
pmcid: 8232613
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71(3):209–249
doi: 10.3322/caac.21660
pubmed: 33538338
Takebayashi K, Nasu K, Okamoto M, Aoyagi Y, Hirakawa T, Narahara H (2020) hsa-miR-100-5p, an overexpressed miRNA in human ovarian endometriotic stromal cells, promotes invasion through attenuation of SMARCD1 expression. Reprod Biol Endocrinol 18(1):31
doi: 10.1186/s12958-020-00590-3
pubmed: 32299427
pmcid: 7161200
Tamai M, Tatarano S, Okamura S, Fukumoto W, Kawakami I, Osako Y, Sakaguchi T, Sugita S, Yonemori M, Yamada Y, Nakagawa M, Enokida H, Yoshino H (2022) microRNA-99a-5p induces cellular senescence in gemcitabine-resistant bladder cancer by targeting SMARCD1. Mol Oncol 16(6):1329–1346
doi: 10.1002/1878-0261.13192
pubmed: 35148461
pmcid: 8936529
Voglis S, Schaller V, Muller T, Gonel M, Winklhofer S, Mangana J, Dummer R, Serra C, Weller M, Regli L, Le Rhun E, Neidert MC (2022) Maximal surgical tumour load reduction in immune-checkpoint inhibitor naive patients with melanoma brain metastases correlates with prolonged survival. Eur J Cancer 17:5158–5168
Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH (2019) Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol 30(9):1479–1486
doi: 10.1093/annonc/mdz197
pubmed: 31236579
pmcid: 6771223
Yan J, Wu X, Yu J, Zhu Y, Cang S (2020) Prognostic role of tumor mutation burden combined with immune infiltrates in skin cutaneous melanoma based on multi-omics analysis. Front Oncol 10:570654
doi: 10.3389/fonc.2020.570654
pubmed: 33240814
pmcid: 7683772
Yoshino T, Pentheroudakis G, Mishima S, Overman MJ, Yeh KH, Baba E, Naito Y, Calvo F, Saxena A, Chen LT, Takeda M, Cervantes A, Taniguchi H, Yoshida K, Kodera Y, Kitagawa Y, Tabernero J, Burris H, Douillard JY (2020) JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions. Ann Oncol 31(7):861–872
doi: 10.1016/j.annonc.2020.03.299
pubmed: 32272210
Zhang L, Shi Z, Zhang F, Chen B, Qiu W, Cai L, Lin X (2023) Ubiquitination-related biomarkers in metastatic melanoma patients and their roles in tumor microenvironment. Front Oncol 13:1170190
doi: 10.3389/fonc.2023.1170190
pubmed: 37274231
pmcid: 10235493
Zhou Y, Xu Q, Tao L, Chen Y, Shu Y, Wu Z, Lu C, Shi Y, Bu H (2020) Enhanced SMARCD1, a subunit of the SWI/SNF complex, promotes liver cancer growth through the mTOR pathway. Clin Sci (lond) 134(12):1457–1472
doi: 10.1042/CS20200244
pubmed: 32514535
Zhou S, Han Y, Yang R, Pi X, Li J (2022) TIMM13 as a prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma (SKCM). Front Surg 9:990749
doi: 10.3389/fsurg.2022.990749
pubmed: 36061054
pmcid: 9428353
Zhu Y, Wang H, Fei M, Tang T, Niu W, Zhang L (2021) Smarcd1 inhibits the malignant phenotypes of human glioblastoma cells via crosstalk with Notch1. Mol Neurobiol 58(4):1438–1452
doi: 10.1007/s12035-020-02190-z
pubmed: 33190170